<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843934</url>
  </required_header>
  <id_info>
    <org_study_id>ACE500</org_study_id>
    <nct_id>NCT00843934</nct_id>
  </id_info>
  <brief_title>Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma</brief_title>
  <acronym>ACE500</acronym>
  <official_title>Randomized Controlled Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and&#xD;
      epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular&#xD;
      Carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>anti-cancer agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.</description>
    <arm_group_label>anti-cancer agent</arm_group_label>
    <other_name>epi-adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.</description>
    <arm_group_label>anti-cancer agent</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be histologically or clinically proven HCC, inoperable, no indication of&#xD;
             local treatment and has measurable lesions.&#xD;
&#xD;
          -  Subject must to be the first experience of TACE.&#xD;
&#xD;
          -  Subject has no extra-hepatic tumor and no obstruction of main portal vein.&#xD;
&#xD;
          -  Subjects must have fully recovered from previous treatment (at least 4 weeks interval&#xD;
             is needed from prior chmotherapy or radiation therapy).&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Child-pugh Class A or B&#xD;
&#xD;
          -  Subject must have adequate functions of bonemarrow, renal, circulatory organs and&#xD;
             appropriate examination results as below:&#xD;
&#xD;
               1. Serum Total Bilirubin 2.0mg/mL&#xD;
&#xD;
               2. WBC 3000/mm3&#xD;
&#xD;
               3. PLT 50000/mm3&#xD;
&#xD;
               4. Hb 9.0g/dL&#xD;
&#xD;
               5. Creatinine ; upper normal limit (UNL)&#xD;
&#xD;
               6. BUN 25mg/dL&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has extra hepatic metastasis.&#xD;
&#xD;
          -  Tumor thrombosis exists at main portal vein.&#xD;
&#xD;
          -  Remarkable artery-portal vein shunt or veno-arterial shunt.&#xD;
&#xD;
          -  Uncontrollable ascites or pleural effusion.&#xD;
&#xD;
          -  History of severe hypersensitivity.&#xD;
&#xD;
          -  Any previous TACE or TAE for HCC.&#xD;
&#xD;
          -  Any previous chemotherapy using epirubicin or CDDP.&#xD;
&#xD;
          -  Complications as below (except chronic hepatitis or liver cirrhosis)&#xD;
&#xD;
               1. Severe heart disease&#xD;
&#xD;
               2. Myocardial infarction within 6 months&#xD;
&#xD;
               3. Renal insufficiency&#xD;
&#xD;
               4. Active infections (except virous hepatitis)&#xD;
&#xD;
               5. Gastrointestinal bleeding&#xD;
&#xD;
               6. Active double cancer&#xD;
&#xD;
               7. Hepatic encephalopathy or heavy mental disorder.&#xD;
&#xD;
          -  Pregnancy or lactation women, or women with suspected pregnancy or men with willing to&#xD;
             get pregnant.&#xD;
&#xD;
          -  Any subject judged by the investigator to be unfit for any reason to participate in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tadatoshi Takayama, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Digestive Surgery Nihon University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masashi Fujii, MD</last_name>
    <phone>+81332981711</phone>
    <email>masashi.fujii@gioncology.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tadatoshi Takayama, MD</last_name>
    <phone>+81339728111</phone>
    <email>Takayama.Tadatoshi@nihon-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Digestive Surgery, Nihon University School of Medicine</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masashi Fujii, MD</last_name>
      <phone>+81332931711</phone>
      <phone_ext>207</phone_ext>
      <email>masashi.fujii@gioncology.jp</email>
    </contact>
    <contact_backup>
      <last_name>Tadatoshi Takayama, MD</last_name>
      <phone>+81339728111</phone>
      <phone_ext>2471</phone_ext>
      <email>Takayama.Tadatoshi@nihon-u.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nihon University</investigator_affiliation>
    <investigator_full_name>Masashi Fujii</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Trans arterial chemoembolization</keyword>
  <keyword>Epirubicin</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

